ATE340589T1 - Impfstoffzusammensetzungen für mukosale abgabe - Google Patents

Impfstoffzusammensetzungen für mukosale abgabe

Info

Publication number
ATE340589T1
ATE340589T1 AT98120803T AT98120803T ATE340589T1 AT E340589 T1 ATE340589 T1 AT E340589T1 AT 98120803 T AT98120803 T AT 98120803T AT 98120803 T AT98120803 T AT 98120803T AT E340589 T1 ATE340589 T1 AT E340589T1
Authority
AT
Austria
Prior art keywords
vaccine compositions
tetanus
mucosal surface
provides
pertussis
Prior art date
Application number
AT98120803T
Other languages
English (en)
Inventor
Mark Roberts
Gordon Dougan
Original Assignee
Medeva Holdings Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medeva Holdings Bv filed Critical Medeva Holdings Bv
Application granted granted Critical
Publication of ATE340589T1 publication Critical patent/ATE340589T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/099—Bordetella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
AT98120803T 1992-04-28 1993-04-28 Impfstoffzusammensetzungen für mukosale abgabe ATE340589T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB929209118A GB9209118D0 (en) 1992-04-28 1992-04-28 Vaccine compositions

Publications (1)

Publication Number Publication Date
ATE340589T1 true ATE340589T1 (de) 2006-10-15

Family

ID=10714652

Family Applications (2)

Application Number Title Priority Date Filing Date
AT93911878T ATE186218T1 (de) 1992-04-28 1993-04-28 Impfstoffzusammensetzungen fuer mukosale abgabe
AT98120803T ATE340589T1 (de) 1992-04-28 1993-04-28 Impfstoffzusammensetzungen für mukosale abgabe

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT93911878T ATE186218T1 (de) 1992-04-28 1993-04-28 Impfstoffzusammensetzungen fuer mukosale abgabe

Country Status (11)

Country Link
US (1) US6562352B1 (de)
EP (2) EP0937462B1 (de)
AT (2) ATE186218T1 (de)
AU (1) AU4267093A (de)
DE (2) DE69326948T2 (de)
DK (2) DK0639081T3 (de)
ES (2) ES2141765T3 (de)
GB (1) GB9209118D0 (de)
GR (1) GR3032381T3 (de)
PT (2) PT937462E (de)
WO (1) WO1993021950A1 (de)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6197548B1 (en) 1990-04-02 2001-03-06 Medeva Pharma Limited Transformed Pichia expressing the pertactin antigen
US7214787B1 (en) * 1993-09-21 2007-05-08 United States Of America As Represented By The Secretary Of The Army Recombinant vaccine against botulinum neurotoxin
JPH11510793A (ja) * 1995-07-07 1999-09-21 オラバックス インク． 胃腸病に対する鼻腔内ワクチン接種
GB9611501D0 (en) * 1996-06-03 1996-08-07 Smithkline Beecham Biolog Vaccine compositions
US6710226B1 (en) 1997-12-02 2004-03-23 Neuralab Limited Transgenic mouse assay to determine the effect of Aβ antibodies and Aβ Fragments on alzheimer's disease characteristics
US6787523B1 (en) 1997-12-02 2004-09-07 Neuralab Limited Prevention and treatment of amyloidogenic disease
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US6913745B1 (en) 1997-12-02 2005-07-05 Neuralab Limited Passive immunization of Alzheimer's disease
US6761888B1 (en) 2000-05-26 2004-07-13 Neuralab Limited Passive immunization treatment of Alzheimer's disease
US7179892B2 (en) 2000-12-06 2007-02-20 Neuralab Limited Humanized antibodies that recognize beta amyloid peptide
US6923964B1 (en) 1997-12-02 2005-08-02 Neuralab Limited Active immunization of AScr for prion disorders
US7790856B2 (en) 1998-04-07 2010-09-07 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US7588766B1 (en) 2000-05-26 2009-09-15 Elan Pharma International Limited Treatment of amyloidogenic disease
US6905686B1 (en) 1997-12-02 2005-06-14 Neuralab Limited Active immunization for treatment of alzheimer's disease
US6750324B1 (en) 1997-12-02 2004-06-15 Neuralab Limited Humanized and chimeric N-terminal amyloid beta-antibodies
US20030147882A1 (en) 1998-05-21 2003-08-07 Alan Solomon Methods for amyloid removal using anti-amyloid antibodies
RU2130778C1 (ru) * 1998-07-31 1999-05-27 Акционерное общество закрытого типа НПК "Комбиотех Лтд" Комбинированная вакцина для иммунопрофилактики вирусного гепатита в, столбняка, дифтерии и коклюша
EP1107783B1 (de) * 1998-09-01 2006-04-05 ELAN CORPORATION, Plc Verfahren zur induktion der zellulären immunantwort und parenterale impfstoff-zusammensetzungen dazu
WO2000012124A1 (en) * 1998-09-01 2000-03-09 Elan Corporation, Plc Oral vaccine compositions
US7087236B1 (en) 1998-09-01 2006-08-08 Merrion Research I Limited Method for inducing a cell-mediated immune response and improved parenteral vaccine formulations thereof
US6787637B1 (en) 1999-05-28 2004-09-07 Neuralab Limited N-Terminal amyloid-β antibodies
UA81216C2 (en) 1999-06-01 2007-12-25 Prevention and treatment of amyloid disease
GB9923060D0 (en) 1999-09-29 1999-12-01 Chiron Spa Vaccine
US6651655B1 (en) 2000-01-18 2003-11-25 Quadrant Technologies Limited Inhaled vaccines
PE20020574A1 (es) 2000-12-06 2002-07-02 Wyeth Corp Anticuerpos humanizados que reconocen el peptido amiloideo beta
US7700751B2 (en) 2000-12-06 2010-04-20 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize β-amyloid peptide
AU2002346424A1 (en) * 2001-11-19 2003-06-10 Becton, Dickinson And Company Pharmaceutical compositions in particulate form
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
TWI306458B (en) 2003-05-30 2009-02-21 Elan Pharma Int Ltd Humanized antibodies that recognize beta amyloid peptide
EP1838348B1 (de) 2004-12-15 2013-06-26 Janssen Alzheimer Immunotherapy Humanisierte amyloid-beta-antikörper zur verbesserung der kognition
US7625560B2 (en) 2004-12-15 2009-12-01 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
US8003097B2 (en) 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
DK2182983T3 (da) 2007-07-27 2014-07-14 Janssen Alzheimer Immunotherap Behandling af amyloidogene sygdomme med humaniserede anti-abeta antistoffer
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8516442D0 (en) * 1985-06-28 1985-07-31 Wellcome Found Cloned antigen
JPS632932A (ja) * 1986-06-23 1988-01-07 Teijin Ltd 経鼻投与用粉末状組成物
EP0267998A1 (de) 1986-11-17 1988-05-25 Institut Pasteur Mittel zur Unterstützung gegen Infektion und Vergiftung von Bordetella
GB8910570D0 (en) * 1989-05-08 1989-06-21 Wellcome Found Acellular vaccine
GB8914122D0 (en) * 1989-06-20 1989-08-09 Wellcome Found Polypeptide expression
IT1248735B (it) * 1990-06-21 1995-01-26 Sclavo Spa Vaccini acellulari contro la pertosse
EP0484621A3 (en) * 1990-07-11 1992-08-26 American Cyanamid Company Efficacious vaccines against bordetella pertussis comprising a combination of individually purified pertussis antigens
JP3415145B2 (ja) * 1991-03-05 2003-06-09 ザ ウエルカム ファウンデーション リミテッド 弱毒化細菌における組換えタンパク質の発現
WO2006034129A2 (en) * 2004-09-17 2006-03-30 Jmar Research, Inc. Systems and methods for detecting scattered light from a particle using illumination incident at an angle

Also Published As

Publication number Publication date
PT639081E (pt) 2000-04-28
EP0639081A1 (de) 1995-02-22
ATE186218T1 (de) 1999-11-15
ES2273391T3 (es) 2007-05-01
US6562352B1 (en) 2003-05-13
DE69326948D1 (de) 1999-12-09
AU4267093A (en) 1993-11-29
EP0639081B1 (de) 1999-11-03
ES2141765T3 (es) 2000-04-01
GB9209118D0 (en) 1992-06-10
EP0937462B1 (de) 2006-09-27
GR3032381T3 (en) 2000-04-27
PT937462E (pt) 2007-01-31
DK0639081T3 (da) 2000-04-10
EP0937462A1 (de) 1999-08-25
DE69326948T2 (de) 2000-03-16
DE69334066D1 (de) 2006-11-09
WO1993021950A1 (en) 1993-11-11
DK0937462T3 (da) 2007-01-29
DE69334066T2 (de) 2007-05-03

Similar Documents

Publication Publication Date Title
ATE340589T1 (de) Impfstoffzusammensetzungen für mukosale abgabe
JP3911058B2 (ja) ストレプトコックス エキワクチン
FR16C0015I2 (fr) Vaccins anticoquelucheux acellulaires et procedes de preparation correspondants
LU90203I2 (fr) Anatoxine diphtérique anatoxine tétanique trois antigènes coquelucheux purifiés (toxine pertussique tp hémagglutinine filamenteuse (haf) et pertactine (protéine de membrane externe 69 kd) et le principal antigène de surface du virus de l'hépatite b (vhb) purfié (infanrix hepb) et ses dérivés pharmaceutiquement acceptables
Podda et al. Phase I clinical trial of an acellular pertussis vaccine composed of genetically detoxified pertussis toxin combined with FHA and 69 kDa
FI924457A0 (fi) Kompositioner och behandlingsfoerfarande foer lunginflammation i djur
Roberts et al. Recombinant P. 69/pertactin: immunogenicity and protection of mice against Bordetella pertussis infection
DK0725653T3 (da) Vaccinepræparater
US6660261B1 (en) Bordetella strain expressing the FHA hybrid, liposomes and vaccines
EP1123711B1 (de) Attenuierte Toxine als Adjuvantien
CA2386023A1 (en) Mucosal dtpa vaccines
PT94030B (pt) Processo de preparacao de antigenios protectores contra as infeccoes e efeitos toxidos de bordetella
JPH06507420A (ja) 粘膜の病原体に対するワクチンとその製法
JPWO2000023107A1 (ja) 減毒化トキシンを含むワクチン製剤
ATE258445T1 (de) Impfstoff beinhaltend bacterin und toxoid aus pasteurella haemolytica typ a-1
RU2185852C1 (ru) Способ вакцинопрофилактики дифтерии и столбняка на крайнем севере
DK0623170T3 (da) Vacciner baseret på streptokinase
Torbicka et al. Serum antibodies to the components of diphtheria-tetanus-pertussis vaccine in Polish children related to vaccination status
Wells et al. Experimental Assessment of Parainfluenza Type 3 Virus Vaccines
CZ20001399A3 (cs) Prostředky a způsoby pro systémové podání orálních vakcín a terapeutických činidel

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0937462

Country of ref document: EP

REN Ceased due to non-payment of the annual fee